Publications by authors named "Jason Melear"

Claim this Profile
A
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Farshad Nassiri, Vikas Patil, Leeor S Yefet, Olivia Singh, Jeff Liu, Jason M Melear

Nat Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Jason Melear

Nat Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma.
Hun Ju Lee, Rod Ramchandren, Judah Friedman, Jason Melear, Ian W Flinn

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Sudhir Manda, Bertrand M Anz, Christopher Benton, E Randolph Broun, Habte A Yimer, Jason M Melear

Hematol Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Jason Melear

Nat Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Jason Melear

Nat Commun· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Farshad Nassiri, Vikas Patil, Leeor S Yefet, Olivia Singh, Jeff Liu, Jason M Melear

Nat Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu, Jason M Melear

EJHaem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
Habte Yimer, Jason Melear, Edward Faber, William I Bensinger, John M Burke

Leuk Lymphoma· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
Paul M Barr, Stephen D Smith, Mark J Roschewski, Susan M O'Brien, Jeff P Sharman, Jason M Melear

Leuk Lymphoma· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Ruth Plummer, Emma Dean, Hendrik-Tobias Arkenau, Charles Redfern, Alexander I Spira, Jason M Melear

Lung Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
Habte Yimer, Jason Melear, Edward Faber, William I Bensinger, John M Burke

Br J Haematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders.
Jason M Melear, Robert M Goldstein, Marlon F Levy, Ernesto P Molmenti, Barry Cooper

Transplantation· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis